Featured Story | Thursday, June 11, 2020 Novo Nordisk plunked down $725 million for France’s Corvidia Therapeutics and its lead program, an anti-IL-6 antibody for the treatment of heart disease related to kidney disease. The Danish drugmaker aims to start a phase 3 study for the drug in 2021 and, if all goes well, Corvidia’s shareholders could ultimately cash out $2.1 billion. read more |
| |
|---|
|
Top Stories Thursday, June 11, 2020 Regeneron has begun clinical development of its anti-SARS-CoV-2 antibody combination REGN-COV2. The adaptive phase 1/2/3 clinical trials will assess the effects of the antibodies on hospitalized and nonhospitalized COVID-19 patients. read more Thursday, June 11, 2020 Next-gen cancer biotech Checkmate Pharmaceuticals has grabbed a healthy series C round toward work on its all-or-nothing immuno-oncology hopeful. read more Thursday, June 11, 2020 Verve Therapeutics launched last year with $58.5 million to create a one-and-done treatment to replace the array of drugs we use to treat heart disease. Now, it’s gearing up to move its first program into the clinic, and it’s snagged another $63 million to do it. read more Thursday, June 11, 2020 French Big Pharma Sanofi, looking to bolster its cancer R&D, has penned a new pact with Alphamab Oncology that focuses on HER2-positive breast cancer. read more Thursday, June 11, 2020 When Astellas closed its $3 billion buyout of Audentes Therapeutics, the J.P. Morgan conference crowd was full of “backhanded congratulations.” They offered Natalie Holles, then the newly minted CEO of Audentes, their kudos along with horror stories of biotechs that had been subsumed by Big Pharma and lost their spunk. read more Thursday, June 11, 2020 An inactivated COVID-19 vaccine by China's state-owned Sinopharm has induced high levels of neutralizing antibodies against the novel coronavirus in animal tests. The vaccine is made from an inactivated form of the virus—a conventional technology— but it could have some advantages over next-generation platforms. read more Thursday, June 11, 2020 A group of independent soda bottle manufacturers working for Coca-Cola has pivoted to help produce the test tubes needed for COVID-19 diagnostic kits. read more |  | Your product is important, and your trial deserves the team that has what it takes. It takes knowledge. It takes passion. It takes commitment. It Takes Avania. Learn more. |
Enrollment Showcase | Sponsored by: University of Florida College of Pharmacy Position yourself as a precision medicine leader with the online graduate program in precision medicine. Learn the latest in genomic technologies and precision medicine therapies from experts in research and implementation. Join the future of health care with the flexibility and convenience of an online program. |
| |
|---|
|
Resources Sponsored by: ICON Download this whitepaper to learn more about the success factors that are required to keep a pandemic respiratory vaccine trial running at optimal speed and efficiency. Sponsored by: Catalent In a series of innovation sessions, Catalent RP Scherer softgel capsules were quickly identified as the ideal solution to drive incremental growth. Learn more. Sponsored by: Blue Matter, strategic consultants in the life sciences White paper describing 7 keys to success for any biopharma company that is entering (or thinking about entering) Europe. Sponsored by: Clinical Ink This white paper covers a Phase III case study; BYOD advantages and misconceptions; and regulatory, copyright, and equivalency considerations. Sponsored by: Clinical Ink Learn how GI specific data capture solutions can support virtual and hybrid trials during COVID-19. Sponsored by: Copyright Clearance Center Dive into the history of biomedical classification and how these systems have evolved to address new technology and use cases. Presented by: ICON Clinical Research Download this whitepaper to learn more about the success factors that are required to keep a pandemic respiratory vaccine trial running at optimal speed and efficiency. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Sponsored by: Clarify Health Pharma launch teams spend significant resources on data and analytics with limited ROI. Read this case study to learn how a Life Sciences company identified two times more patients best suited for therapy, using Clarify’s deep and longitudinal patient and HCP insights. Sponsored by: Frontage Laboratories, Inc. Listen to our brand-new Frontage Laboratories podcast where you’ll take home tips for developing residual host cell proteins ELISA assay for biopharmaceutical products using commercial kits. Wednesday, May 20, 2020 | Time: 10am-3.30pm (BST) Join us for a day of discovery as global experts in Cardiology, Pharmacology and Diabetes discuss state of the art methods in early phase clinical research. Sponsored by: Oracle Health Sciences Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual." Sponsored by: Outer Edge Technology Businesses must maintain pre-pandemic levels of productivity with smaller IT budgets. Learn why an effective Cloud Strategy is imperative for success in these unprecedented times. | 
